Achieving selective inhibition of chemokines with structurally well-defined heparan sulfate (HS) oligosaccharides can provide important insights into cancer cell migration and metastasis. However, HS is highly heterogeneous in chemical composition, which limits its therapeutic use. Here, we report the rational design and synthesis of N-unsubstituted (NU) and N-acetylated (NA) heparan sulfate tetrasaccharides that selectively inhibit structurally homologous chemokines. HS analogs were produced by divergent synthesis, where fully protected HS tetrasaccharide precursor was subjected to selective deprotection and regioselectively O-sulfated, and O-phosphorylated to obtain 13 novel HS tetrasaccharides. HS microarray and SPR analysis with a wide range of chemokines revealed the structural significance of sulfation patterns and NU domain in chemokine activities for the first time. Particularly, HT-3,6S-NH revealed selective recognition by CCL2 chemokine. Further systematic interrogation of the role of HT-3,6S-NH in cancer demonstrated an effective blockade of CCL2 and its receptor CCR2 interactions, thereby impairing cancer cell proliferation, migration and invasion, a step towards designing novel drug molecules.Small molecules that bind with high affinity and specificity to fibrils of the α-synuclein (αS) protein have the potential to serve as positron emission tomography (PET) imaging probes to aid in the diagnosis of Parkinson's disease and related synucleinopathies. To identify such molecules, we employed an ultra-high throughput in silico screening strategy using idealized pseudo-ligands termed exemplars to identify compounds for experimental binding studies. For the top hit from this screen, we used photo-crosslinking to confirm its binding site and studied the structure-activity relationship of its analogs to develop multiple molecules with nanomolar affinity for αS fibrils and moderate specificity for αS over Aβ fibrils. Lastly, we demonstrated the potential of the lead analog as an imaging probe by measuring binding to αS-enriched homogenates from mouse brain tissue using a radiolabeled analog of the identified molecule. This study demonstrates the validity of our powerful new approach to the discovery of PET probes for challenging molecular targets.Ecosystems are spatially heterogenous in plant community composition and function. Shrub occurrence in grasslands is a visually striking example of this, and much research has been conducted to understand the functional implications of this pattern. Within savannah ecosystems, the presence of tree and shrub overstories can have significant impacts on the understory herbaceous community. The exact outcomes, however, are likely a function of the spatial arrangement and traits of the overstory species. Here we test whether there are functional linkages between the spatial patterning of a native shrub and the standing biomass, community composition, and overall nutrient cycling of a neighbouring grassland understory communities within the Aspen Parkland of central Alberta, Canada. In a paired grassland-shrub stand study, we found the native shrub, Elaeagnus commutata, has relatively few stand-level impacts on the composition and standing biomass of the ecosystem. One factor contributing to these limited effects may be the overdispersion of shrub stems at fine spatial scales, preventing areas of deep shade. When we looked across a shrub density gradient and incorporated shrub architecture into our analyses, we found these shrub traits had significant associations with species abundance and root biomass in the understory community. These results suggest that stem dispersion patterns, as well as local stand architecture, are influential in determining how shrubs may affect their herbaceous plant understory. Thus, it is important to incorporate shrub spatial and architectural traits when assessing shrub-understory interactions.Bark contributes approximately 20% to the total above-ground biomass of trees, yet bark is not properly accounted for when estimating carbon sequestered by trees. Current allometric functions estimate tree volume from diameter measured over the bark, and derive bark density and carbon content from estimates for wood. As the bark density of hardwood species is 40%-50% lower than the wood density, but nearly equivalent in conifers, bark carbon is overestimated for most species. The latter is further exacerbated by variation in bark volume with bark surface morphology.Fissured bark volume is overestimated by diameter over bark measurements by up to 40%. The vacant space in fissures can be accounted for by a bark fissure index (BFI). We calculate bark carbon for Australian species from a non-destructive and effective BFI using bark thickness measured in the field.Bark volume, and in turn bark carbon, scaled inversely with tree size (diameter) so that bark volume comprised 42% of small trees (10 cm diameter at breast height, DBH) but 23% of large trees (50 cm DBH). Our BFI method using a bark thickness gauge (BGM) yielded similar results than using the less time-efficient contour gauge method (CM) to estimate BFI (bias BGM-CM -1.3%, non-significant at p = 0.72). Both BGM and CM had an error of less then 4% compared to digitized BFI from destructive sampled stem disks. An average of 15 bark gauge measurements per tree estimated bark thickness (and inconsequence BFI) for both fissured and unfissured bark with less then 20% error relative to the exact value.Using the bark gauge method, BFI can be rapidly measured from large numbers of trees needed for estimating bark carbon at the community level and modelling carbon uptake, storage and cycling in woody biomes.Clinical research in hematologic malignancies is continually advancing with emerging concepts in therapy and evolving results from clinical protocols. Targeting of the PI3K pathway remains a valuable treatment across both hematologic and solid malignancies. There are currently four United States Food and Drug Administration (FDA)-approved PI3K inhibitors, with several others in development. Copanlisib is a pan-PI3K inhibitor currently FDA-approved for the treatment of relapsed/refractory follicular lymphoma (FL) following two lines of therapy. Since FDA approval, there have been further investigations into the long-term safety profile of copanlisib, as well as treatment of FL and other lymphoma subtypes, both indolent and aggressive. Here, we review the most recent available data from clinical trials, describe the management of the most common side effects, and explore future concepts. https://www.selleckchem.com/ The use of copanlisib as part of a combination therapy for various hematologic malignancies will also be discussed. Copanlisib is a unique drug compared with other PI3K inhibitors, with remarkable potential to improve our armamentarium in cancer treatment.